Stocks making the biggest moves midday: Rogers, United Therapeutics, Moderna, FormFactor & more
Rogers rose 10% on higher earnings guidance ($3.80 vs. $3.65 consensus). Liquidia fell 25% after a patent infringement ruling, while United Therapeutics gained 15%. Jabil dropped 7% despite beating earnings and revenue estimates. Concentrix climbed 5% on strong earnings but issued weak guidance. Moderna fell 7% after a Citi downgrade. FormFactor gained 8% on a Deutsche Bank buy rating. Cal-Maine Foods declined 2% on a wider-than-expected loss.
How this was made
The 30-second read
Why it matters
The article aggregates multiple independent catalysts, providing traders with a quick scan of actionable events across sectors.
Market read
Multiple stocks experienced notable price moves due to fresh earnings, legal rulings, and analyst actions, offering short‑term trading ideas.
What to watch
Potential downstream effects of the patent ruling on other biotech firms and supply‑chain considerations for FormFactor.
Background
A midday roundup highlighting the biggest stock moves, each driven by distinct corporate news items.
Ticker impact
Liquidia shares plunged ~25% after a Delaware court ruled it infringed United Therapeutics patents.
likely pressure as the market prices in the adverse legal outcome
Court ruling is a material legal setback; shares already fell sharply.
United Therapeutics surged ~15% following the same court decision that favored its patent claims.
likely upside as investors reward the favorable legal outcome
Legal win removes uncertainty and could boost licensing opportunities.
Jabil fell >7% despite beating Q4 earnings, after reporting revenue and EPS that exceeded expectations.
potential continued pressure as market digests unclear guidance
Price drop indicates investors may be wary of future outlook despite current beat.
Concentrix rose 5% after reporting Q3 adjusted earnings above expectations, but revenue guidance missed estimates.
moderate upside as the earnings beat may outweigh guidance miss
Investors weigh strong earnings against weaker guidance.
Moderna fell 7% after Citi downgraded the stock to sell, citing a price target 60% below the current price.
likely pressure as the downgrade may trigger sell orders
Downgrade with a large price target gap is a strong bearish signal.
FormFactor shares rose 8% after Deutsche Bank initiated coverage with a buy rating, citing its role as a second source of probe cards for Nvidia GPUs.
likely upside as coverage may attract new buyers
Analyst buy rating and strategic relevance support price gains.
Cal-Maine Foods slid 2% after reporting a wider-than-expected Q1 loss of $1.26 per share versus $0.77 expected.
slight pressure as the loss beat expectations
Loss miss may cause short‑term sell pressure.
Market effects
Legal outcomes for biotech (Liquidia, United Therapeutics) and earnings beats/misses for tech and consumer services may shift sector sentiment.
U.S. equities impacted across multiple sectors during midday trading.
Limited to U.S. markets; no broader macro or geopolitical effect.
Counterpoint
Some investors may view the legal win for United Therapeutics as a short‑term rally, but the broader biotech risk remains high.
Key entities
- companyLiquidia
Biotech firm facing patent infringement ruling.
- companyUnited Therapeutics
Biotech firm benefiting from patent ruling.
- companyJabil
Electronics manufacturer reporting Q4 earnings beat.
- companyConcentrix
Business services firm with earnings beat but weak guidance.
- companyModerna
Pharma company downgraded by Citi.
